Lifecore Biomedical Inc
NASDAQ:LFCR
Lifecore Biomedical Inc
Capital Expenditures
Lifecore Biomedical Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Capital Expenditures
-$14.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
Hershey Co
NYSE:HSY
|
Capital Expenditures
-$693.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-6%
|
|
|
General Mills Inc
NYSE:GIS
|
Capital Expenditures
-$693.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
Kellogg Co
NYSE:K
|
Capital Expenditures
-$628m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Capital Expenditures
-$1.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Capital Expenditures?
Capital Expenditures
-14.8m
USD
Based on the financial report for Nov 24, 2024, Lifecore Biomedical Inc's Capital Expenditures amounts to -14.8m USD.
What is Lifecore Biomedical Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
0%
Over the last year, the Capital Expenditures growth was 39%. The average annual Capital Expenditures growth rates for Lifecore Biomedical Inc have been 21% over the past three years , 19% over the past five years .
You don't have any saved screeners yet